MDXX-class molecules and clinical-grade MDMA developer PharmAla Biotech and distribution partner Shaman Pharma Corp. (affiliated with GMP-compliant CCrest Labs) received Health Canada’s approval to provide proprietary LaNeo MDMA capsules to a Canadian physician for patient treatment under the Special Access Program (SAP.)
The federal agency has confirmed that this is the first-ever authorization of an MDMA-assisted therapy treatment under the SAP.
See also: Psychedelic Therapies Soon Available In Australia Via Incannex Healthcare And Subsidiary
The partnership will not charge …